Medexus Pharmaceuticals Inc
MDP
Company Profile
Business description
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
Contact
10 King Street East
Suite 600
TorontoONM5C 1C3
CANT: +1 514 762-2626
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
102
Stocks News & Analysis
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.60 | 35.90 | 0.41% |
| CAC 40 | 8,087.91 | 9.43 | 0.12% |
| DAX 40 | 25,417.56 | 43.14 | 0.17% |
| Dow JONES (US) | 51,481.51 | 347.11 | -0.67% |
| FTSE 100 | 10,736.54 | 51.66 | 0.48% |
| HKSE | 24,558.15 | 84.36 | -0.34% |
| NASDAQ | 26,820.38 | 248.34 | -0.92% |
| Nikkei 225 | 65,481.27 | 396.35 | -0.60% |
| NZX 50 Index | 13,683.63 | 147.05 | -1.06% |
| S&P 500 | 7,683.69 | 59.72 | -0.77% |
| S&P/ASX 200 | 8,709.30 | 29.60 | 0.34% |
| SSE Composite Index | 3,830.45 | 6.83 | 0.18% |